Doing an excellent job of talking your own investment down (on a...

Doing an excellent job of talking your own investment down (on a CR being a given). Oh well, gives me opportunity to buy into PAR at ever lower levels. Self fulfilling level 2 chaos trading of markets in full display on PAR Hot Copper threads. It now trades below the mkt cap of another shared investment you did indeed "ridicule" me for daring to compare to Paradigm's potential success a couple of years ago, that is already in US/EU markets earning actual revenues with a top 5 Pharma in only one smaller aspect of its excellent Australian evolved bio-technology.

The CR sentiment has certainly won over the deal sentiment on both these threads and trading - the two not unrelated of course. If one does indeed occur (it is not a given and a very risky sell on prediction of that versus an early deal SP pop) it will evidently only be a short term raise to carry it through any protracted deal negotiations that have literally been all but assured by PR and co. Just a little reminder of the last CR's featured a 2022 $66 million raising with a $46 million insto placement and a $20 million retail at a long ago forgotten $1.30 to fund "the company into CY2024" and a 2023 $30 million insto' placement and $18 million retail aspect at $0.43 per share "to fund Paradigm through to mid CY25 (without additional licensing revenue) including the top-line readout from the Pivotal Phase 3 OA clinical trial." (Insto's have been just as screwed as retail by PAR).

Good luck PAR investors. Its been a horrible, horrible carry, but this phoenix surely about to rise from the ashes in the next six months with deals on the back of deals on tardy phase III progression at last.

Long term if you are buying at $0.22 on secondary or indeed $0.17 on primary following a tie over CR (NOT a given), you are investing at great comparative levels irresepctive of which - unlike those unfortunate Insto and retail investors who bought at $1.30.